May 27, 2019
Japanese biotech Ribomic said on May 24 that it has filed a patent application for its anti-midkine aptamer RBM-001 as a “treatment for diseases associated with abnormalities in bone formation and bone metabolism.” Ribomic, a startup originating from the University...read more